JP Morgan Chase’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-721
| Closed | -$116 | – | 7873 |
|
|
2024
Q4 | $116 | Hold |
721
| – | – | ﹤0.01% | 6989 |
|
|
2024
Q3 | $167 | Hold |
721
| – | – | ﹤0.01% | 6926 |
|
|
2024
Q2 | $392 | Hold |
721
| – | – | ﹤0.01% | 6710 |
|
|
2024
Q1 | $735 | Hold |
721
| – | – | ﹤0.01% | 6673 |
|
|
2023
Q4 | $411 | Hold |
721
| – | – | ﹤0.01% | 6954 |
|
|
2023
Q3 | $750 | Hold |
721
| – | – | ﹤0.01% | 6678 |
|
|
2023
Q2 | $1.02K | Hold |
721
| – | – | ﹤0.01% | 6453 |
|
|
2023
Q1 | $1K | Hold |
721
| – | – | ﹤0.01% | 6568 |
|
|
2022
Q4 | $1K | Sell |
721
-1,523
| -68% | -$4.45K | ﹤0.01% | 6460 |
|
|
2022
Q3 | $10K | Buy |
2,244
+715
| +47% | +$3.03K | ﹤0.01% | 5971 |
|
|
2022
Q2 | $6K | Sell |
1,529
-19,912
| -93% | -$56.7K | ﹤0.01% | 6135 |
|
|
2022
Q1 | $102K | Buy |
21,441
+4,210
| +24% | +$12.7K | ﹤0.01% | 5502 |
|
|
2021
Q4 | $63K | Sell |
17,231
-560,446
| -97% | -$2.99M | ﹤0.01% | 5859 |
|
|
2021
Q3 | $4.63M | Buy |
577,677
+563,758
| +4,050% | +$5.56M | ﹤0.01% | 3093 |
|
|
2021
Q2 | $158K | Buy |
+13,919
| New | +$140K | ﹤0.01% | 5351 |
|
|
2020
Q3 | – | Sell |
-1,003
| Closed | -$9K | – | 5847 |
|
|
2020
Q2 | $9K | Buy |
+1,003
| New | +$15.1K | ﹤0.01% | 5147 |
|
|
2018
Q4 | – | Sell |
-1,413
| Closed | -$99K | – | 5979 |
|
|
2018
Q3 | $99K | Sell |
1,413
-798
| -36% | -$60.6K | ﹤0.01% | 4958 |
|
|
2018
Q2 | $164K | Buy |
2,211
+2,124
| +2,441% | +$189K | ﹤0.01% | 4653 |
|
|
2018
Q1 | $8K | Sell |
87
-554
| -86% | -$95K | ﹤0.01% | 5200 |
|
|
2017
Q4 | $83K | Buy |
641
+306
| +91% | +$28.7K | ﹤0.01% | 4726 |
|
|
2017
Q3 | $22K | Buy |
+335
| New | +$27.4K | ﹤0.01% | 4627 |
|
|
2017
Q1 | – | Sell |
-121
| Closed | -$15K | – | 5272 |
|
|
2016
Q4 | $15K | Buy |
121
+69
| +133% | +$9.6K | ﹤0.01% | 4747 |
|
|
2016
Q3 | $8K | Sell |
52
-163
| -76% | -$23K | ﹤0.01% | 4328 |
|
|
2016
Q2 | $25K | Hold |
215
| – | – | ﹤0.01% | 4185 |
|
|
2016
Q1 | $24K | Buy |
215
+15
| +8% | +$2.27K | ﹤0.01% | 4057 |
|
|
2015
Q4 | $38K | Buy |
200
+90
| +82% | +$16.8K | ﹤0.01% | 3975 |
|
|
2015
Q3 | $19K | Sell |
110
-367
| -77% | -$132K | ﹤0.01% | 3838 |
|
|
2015
Q2 | $301K | Buy |
477
+301
| +171% | +$160K | ﹤0.01% | 3719 |
|
|
2015
Q1 | $91K | Buy |
176
+85
| +93% | +$42.9K | ﹤0.01% | 3908 |
|
|
2014
Q4 | $49K | Buy |
+91
| New | +$41K | ﹤0.01% | 4146 |
|
Other funds holding VIRX
XT
UCFA
WA
BBA
RM
JP Morgan Chase's VIRX Position: Q1 2025 in Review
JP Morgan Chase sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 721 shares — an estimated $116 sold.
JP Morgan Chase first reported a position in VIRX in Q4 2014 and held it in 30 quarters. The position peaked at $4.63M in Q3 2021. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.
- JP Morgan Chase reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- JP Morgan Chase sold 721 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $116.
- JP Morgan Chase first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 30 quarters.
- JP Morgan Chase's Viracta Therapeutics, Inc. Common Stock position peaked at $4.63M in Q3 2021.
- 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.
Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.